Literature DB >> 10447392

Measurement of human antibodies to type III group B Streptococcus.

D L Kasper, M R Wessels, H K Guttormsen, L C Paoletti, M S Edwards, C J Baker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10447392      PMCID： PMC96744          DOI： 10.1128/IAI.67.8.4303-4305.1999

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


× No keyword cloud information.
  15 in total

1.  Opsonic activity of human IgG and IgM antibody for type III group B streptococci.

Authors:  B F Anthony; N F Concepcion
Journal:  Pediatr Res       Date:  1989-10       Impact factor: 3.756

2.  Intravenous immunoglobulin in the treatment of neonatal sepsis: therapeutic strategies and laboratory studies.

Authors:  G W Fischer; V G Hemming; K W Hunter; H Gloser; H Bachmayer; C E Von Pilar; T Helting; L E Weisman; S R Wilson; P A Baron
Journal:  Pediatr Infect Dis       Date:  1986 May-Jun

3.  Structural determination and serology of the native polysaccharide antigen of type-III group B Streptococcus.

Authors:  H J Jennings; K G Rosell; D L Kasper
Journal:  Can J Biochem       Date:  1980-02

Review 4.  Group B streptococcus.

Authors:  A Schuchat
Journal:  Lancet       Date:  1999-01-02       Impact factor: 79.321

5.  Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci.

Authors:  B F Anthony; N F Concepcion; C A Wass; D C Heiner
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

6.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.

Authors:  C J Baker; D L Kasper
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

7.  Conformational aspects critical to the immunospecificity of the type III group B streptococcal polysaccharide.

Authors:  H J Jennings; C Lugowski; D L Kasper
Journal:  Biochemistry       Date:  1981-08-04       Impact factor: 3.162

8.  Influence of preimmunization antibody levels on the specificity of the immune response to related polysaccharide antigens.

Authors:  C J Baker; D L Kasper; M S Edwards; G Schiffman
Journal:  N Engl J Med       Date:  1980-07-24       Impact factor: 91.245

9.  Role of antibody to native type III polysaccharide of group B Streptococcus in infant infection.

Authors:  C J Baker; M S Edwards; D L Kasper
Journal:  Pediatrics       Date:  1981-10       Impact factor: 7.124

10.  Immunodeterminant specificity of human immunity to type III group B streptococcus.

Authors:  D L Kasper; C J Baker; R S Baltimore; J H Crabb; G Schiffman; H J Jennings
Journal:  J Exp Med       Date:  1979-02-01       Impact factor: 14.307
View more
  5 in total

1.  Utilization of serologic assays to support efficacy of vaccines in nonclinical and clinical trials: meeting at the crossroads.

Authors:  Dace V Madore; Bruce D Meade; Fran Rubin; Carolyn Deal; Freyja Lynn
Journal:  Vaccine       Date:  2010-05-12       Impact factor: 3.641

Review 2.  Group B Streptococcus vaccine development: present status and future considerations, with emphasis on perspectives for low and middle income countries.

Authors:  Miwako Kobayashi; Johan Vekemans; Carol J Baker; Adam J Ratner; Kirsty Le Doare; Stephanie J Schrag
Journal:  F1000Res       Date:  2016-09-22

Review 3.  Protection Against Invasive Infections in Children Caused by Encapsulated Bacteria.

Authors:  Manish Sadarangani
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

4.  Novel Multiplex Immunoassays for Quantification of IgG against Group B Streptococcus Capsular Polysaccharides in Human Sera.

Authors:  Giada Buffi; Bruno Galletti; Maria Stella; Daniela Proietti; Evita Balducci; Maria Rosaria Romano; Elena Mori; Monica Fabbrini; Marzia Monica Giuliani; Francesco Berti; Immaculada Margarit
Journal:  mSphere       Date:  2019-08-07       Impact factor: 4.389

5.  Progress toward a group B streptococcal vaccine.

Authors:  Joon Young Song; Jae Hyang Lim; Sangyong Lim; Zhi Yong; Ho Seong Seo
Journal:  Hum Vaccin Immunother       Date:  2018-07-16       Impact factor: 3.452
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.